Plug Power Inc (NASDAQ:PLUG) has been one of the most volatile stocks over the past few months. It has been called a “penny stock” by Citron Research. And recently, Global Equities Research analyst Trip Chowdhry said that Plug Power and its fuel cell technology aren’t the right fit for the car market. Many consider it a speculative play which has little potential to turn profitable. But Plug Power Inc (NASDAQ:PLUG)’s long-term future may not be as bad as some predict. The Latham, New York-based company’s foray into the new markets, increased revenue stream, and the recent stock offering could work together to lay a solid foundation for Plug Power’s long-term future. Plug Power Inc. (NASDAQ:PLUG) weekly performance is -22.39%. On last trading day company shares ended up $3.64. Analysts mean target price for the company is $7.75. Plug Power Inc. (NASDAQ:PLUG) distance from 50-day simple moving average (SMA50) is -42.73%.
Avanir Pharmaceuticals, Inc. (NASDAQ:AVNR) reported financial results for the three and six months ended March 31, 2014. Total net revenues for the second quarter fiscal 2014 were $26.9 million, compared with $17.4 million for the comparable quarter in fiscal 2013, representing 55 percent year-over-year growth. Total net revenues consist of NUEDEXTA revenue, Abreva® royalties and co-promotion revenues. Avanir Pharmaceuticals Inc. (NASDAQ:AVNR) shares advanced 3.38% in last trading session and ended the day on $4.59. AVNR gross Margin is 94.60% and its return on assets is -99.70%.Avanir Pharmaceuticals Inc. (NASDAQ:AVNR) quarterly performance is 33.04%.
Idera Pharmaceuticals, Inc. (NASDAQ: DRA), a clinical-stage biotechnology company developing novel therapeutics for orphan patient populations with B-cell lymphomas and autoimmune diseases, announced that it has entered into an agreement with Abbott, the global healthcare company, for the development of an in vitro companion diagnostic test for use in Idera’s clinical development programs to treat certain genetically defined forms of B-cell lymphoma with IMO-8400.Idera Pharmaceuticals Inc. (NASDAQ:IDRA) shares moved down -2.01% in last trading session and was closed at $2.44, while trading in range of $2.44 – $2.90. Idera Pharmaceuticals Inc. (NASDAQ:IDRA) year to date (YTD) performance is -47.30%.
Zillow (NASDAQ:Z)‘s stock had its “hold” rating reiterated by research analysts at Deutsche Bank in a report released on Thursday, AnalystRatings.Net reports. They currently have a $78.00 price objective on the stock, down from their previous price objective of $80.00. Deutsche Bank’s price target suggests a potential downside of 19.91% from the company’s current price. Zillow Inc. (NASDAQ:Z) ended the last trading day at $97.39. Company weekly volatility is calculated as 7.95% and price to cash ratio as 13.10.Zillow Inc. (NASDAQ:Z) showed a negative weekly performance of -9.00%.
Leave a Reply